Nanovesicles system for rapid-onset sublingual delivery containing sodium tanshinone IIA sulfonate: In vitro and in vivo evaluation

Journal of Pharmaceutical Sciences

Volumn 102, Issue 7, 2013, Pages 2332-2340

  Zhu, Hongda ^a   Hao, Jianjun ^b   Chen, Huabing ^c   Jiang, Shanshan ^c   Liu, Mingxing ^a   Sun, Honghao ^a   Xu, Huibi ^c   Zhang, Jiemei ^b   Yang, Xiangliang ^c  

^a HUBEI UNIVERSITY OF TECHNOLOGY   (China)

^b The First Hospital of Wuhan City   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Absorption enhancer; Drug transport; Formulation vehicle; Nanotechnology; Nanovesicles; Rapid onset; Sublingual; Transmucosal drug delivery

Indexed keywords

DODECYL SULFATE SODIUM; HYALURONIC ACID; PHOSPHATIDYLCHOLINE; PROPYLENE GLYCOL; TANSHINONE IIA; TANSHINONE IIA SULFONIC ACID; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG FORMULARY; DRUG PENETRATION; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; NANOTECHNOLOGY; NANOVESICLES SYSTEM; NONHUMAN; RABBIT; ST SEGMENT; SUBLINGUAL DRUG ADMINISTRATION;

EID: 84879018900     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23512     Document Type: Article

References (31)

1. Mathias NR, Hussain MA. 2010. Non-invasive systemic drug delivery: Developability considerations for alternate routes of administration. J Pharm Sci 99(1):1-20.
2. Hearnden V, Sankar V, Hull K, Juras DV, Greenberg M, Kerr AR, Lockhart PB, Patton LL, Porter S, Thornhill MH. 2012. New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Adv Drug Deliv Rev 64(1):16-28.
3. Shry EA, Dacus J, Van De Graaff E, Hjelkrem M, Stajduhar KC, Steinhubl SR. 2002. Usefulness of the response to sublingual nitroglycerin as a predictor of ischemic chest pain in the emergency department. Am J Cardiol 90(11):1264-1266.
4. Bredenberg S, Duberg M, Lennernas B, Lennernas H, Pettersson A, Westerberg M, Nystrom C. 2003. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Biopharm 20(3):327-334.
5. Bayrak Z, Tas C, Tasdemir U, Erol H, Ozkan CK, Savaser A, Ozkan Y. 2011. Formulation of zolmitriptan sublingual tablets prepared by direct compression with different polymers: In vitro and in vivo evaluation. Eur J Pharm Biopharm 78(3):499-505.
6. Patel VF, Liu F, Brown MB. 2011. Advances in oral transmucosal drug delivery. J Control Release 153(2):106-116.
7. de la Fuente M, Csaba N, Garcia-Fuentes M, Alonso MJ. 2008. Nanoparticles as protein and gene carriers to mucosal surfaces. Nanomedicine (Lond) 3(6):845-857.
8. Kumar A, Pathak K, Bali V. 2012. Ultra-adaptable nanovesicular systems: A carrier for systemic delivery of therapeutic agents. Drug Discov Today 17(21-22):1233-1241.
9. Yang TZ, Wang XT, Yan XY, Zhang Q. 2002. Phospholipid deformable vesicles for buccal delivery of insulin. Chem Pharm Bull (Tokyo) 50(6):749-753.
10. Xu HB, Huang KX, Zhu YS, Gao QH, Wu QZ, Tian WQ, Sheng XQ, Chen ZX, Gao ZH. 2002. Hypoglycaemic effect of a novel insulin buccal formulation on rabbits. Pharmacol Res 46(5):459-467.
11. Horvat S, Feher A, Wolburg H, Peter S, Veszelka S, Toth A, Lorand K, Anita K, Gabor B, Levente K, Eros I, Szabo-Revesz P, Deli MA. 2009. Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue. Eur J Pharm Biopharm 72(1):252-259.
12. Shang QH, Xu H, Huang L. 2012. Tanshinone IIA: A promising natural cardioprotective agent. Evid Based Complement Altern Med 2012:1-7.
13. Fu JJ, Huang HQ, Liu JJ, Pi RB, Chen JW, Liu PQ. 2007. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol 568(1-3):213-221.
14. Han JY, Fan JY, Horie Y, Miura S, Cui DH, Ishii H, Hibi T, Tsuneki H, Kimura I. 2008. Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol Ther 117(2):280-295.
15. Jiang BH, Zhang L, Wang YC, Li M, Wu WY, Guan SH, Liu X, Yang M, Wang JC, Guo DA. 2009. Tanshinone IIA sodium sulfonate protects against cardiotoxicity induced by doxorubicin in vitro and in vivo. Food Chem Toxicol 47(7):1538-1544.
16. Yan FF, Liu YF, Liu Y, Zhao YX. 2009. Sulfotanshinone sodium injection could decrease fibrinogen level and improve clinical outcomes in patients with unstable angina pectoris. Int J Cardiol 135(2):254-255.
17. Chen HB, Zhu HD, Zheng JN, Mou DS, Wan JL, Zhang JY, Shi TL, Zhao YJ, Xu HB, Yang XL. 2009. Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin. J Control Release 139(1):63-72.
18. Yan Y, OW, Zhao X, Ye X, Zhang C, Hao J, He J, Zhu X, Xu H, Yang X. 2010. Effect of essential oil of Syringa pinnatifolia Hemsl. var. alashanensis on ischemia of myocardium, hypoxia and platelet aggregation. J Ethnopharmacol 131(2):248-255.
19. Li M, Yu CM, Cheng L, Wang M, Gu X, Lee KH, Wang T, Sung YT, Sanderson JE. 2006. Repair of infarcted myocardium by an extract of Geum japonicum with dual effects on angiogenesis and myogenesis. Clin Chem 52(8):1460-1468.
20. Madhav NVS, Shakya AK, Shakya P, Singh K. 2009. Orotransmucosal drug delivery systems: A review. J Control Release 140(1):2-11.
21. Wang YF, Zuo Z, Chow MSS. 2009. HO-1-u-1 model for screening sublingual drug delivery-Influence of pH, osmolarity and permeation enhancer. Int J Pharm 370(1-2):68-74.
22. Nicolazzo JA, Reed BL, Finnin BC. 2005. Buccal penetration enhancers-how do they really work? J Control Release 105(1-2):1-15.
23. Nicolazzo JA, Reed BL, Finnin BC. 2004. Assessment of the effects of sodium dodecyl sulfate on the buccal permeability of caffeine and estradiol. Int J Pharm 93(2):431-440.
24. Seaman CW, Whittingham A, Guest R, Warren N, Olson MJ, Guerriero FJ, Adriaens E, De Wever B. 2010. An evaluation of a cultured human corneal epithelial tissue model for the determination of the ocular irritation potential of pharmaceutical process materials. Toxicol In Vitro 24(6):1862-1870.
25. Ludwig A. 2005. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 57(11):1595-1639.
26. de la Fuente M, Ravina M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ. 2010. Chitosan-based nanostructures: A delivery platform for ocular therapeutics. Adv Drug Deliv Rev 62(1):100-117.
27. Cho KY, Chung TW, Kim BC, Kim MK, Lee JH, Wee WR, Cho CS. 2003. Release of ciprofloxacin from poloxamer-graft-hyaluronic acid hydrogels in vitro. Int J Pharm 260(1):83-91.
28. Sandri G, Rossi S, Ferrari F, Bonferoni MC, Zerrouk N, Caramella C. 2004. Mucoadhesive and penetration enhancement properties of three grades of hyaluronic acid using porcine buccal and vaginal tissue, Caco-2 cell lines, and rat jejunum. J Pharm Pharmacol 56(9):1083-1090.
29. Hornof M, de la Fuente M, Hallikainen M, Tammi RH, Urtti A. 2008. Low molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates CD44 receptor mediated uptake in human corneal epithelial cells. J Gene Med 10(1):70-80.
30. Travers A. 2007. Achieving optimal care for ST-segment elevation myocardial infarction in Canada. Can Med Assoc J 176(13):1843-1844.
31. McInnes F, Clear N, James G, Stevens HNE, Vivanco U, Humphrey M. 2008. Evaluation of the clearance of a sublingual buprenorphine spray in the beagle dog using gamma scintigraphy. Pharm Res 25(4):869-874.